Core Insights - Steris reported revenue of $1.46 billion for the quarter ended September 2025, reflecting a year-over-year increase of 9.9% and surpassing the Zacks Consensus Estimate of $1.43 billion by 2.31% [1] - The company's EPS for the quarter was $2.47, an increase from $2.14 in the same quarter last year, also exceeding the consensus estimate of $2.38 by 3.78% [1] Revenue Performance - Healthcare revenues reached $1.03 billion, exceeding the average estimate of $1.01 billion by analysts, marking a 9.5% increase year-over-year [3] - Healthcare Products - Consumables generated $374.2 million, surpassing the estimated $357.5 million, with a year-over-year growth of 9.5% [3] - Healthcare Products - Capital Equipment reported $259.4 million, slightly below the average estimate of $268.96 million, but still showing a 3.9% increase year-over-year [3] - Healthcare Products - Service revenues were $400.1 million, exceeding the estimate of $374.76 million, reflecting a significant year-over-year increase of 13.4% [3] - Life Sciences revenues totaled $145 million, surpassing the estimated $137.24 million, with a year-over-year growth of 13.3% [3] - Applied Sterilization Technologies (AST) revenues were $281.5 million, slightly above the average estimate of $281.02 million, representing a 9.7% year-over-year increase [3] - Life Sciences - Service revenues reached $35.8 million, below the estimate of $36.79 million, but still showing a 9.1% increase year-over-year [3] - Life Sciences - Capital Equipment generated $31.9 million, exceeding the estimate of $27.85 million, with a notable year-over-year growth of 38.6% [3] - Life Sciences - Consumables reported $77.2 million, surpassing the estimated $71.75 million, reflecting a 7% increase year-over-year [3] Operating Income - Operating income for Healthcare was $259.5 million, exceeding the average estimate of $239.46 million [3] - Corporate and Other reported an operating loss of $109.9 million, slightly worse than the average estimate of $-106.78 million [3] - Operating income for Applied Sterilization Technologies (AST) was $127.6 million, below the average estimate of $132.54 million [3]

Core Viewpoint - STERIS plc (STE) is set to release its fourth-quarter fiscal 2025 results on May 14, with expectations of revenue growth and increased earnings per share (EPS) compared to the previous year [1][2]. Financial Performance - The Zacks Consensus Estimate for revenues is $1.48 billion, reflecting a 4.2% increase from the prior year [2]. - The Zacks Consensus Estimate for EPS is $2.58, indicating a year-over-year increase of 7.1% [2]. - In the last reported quarter, STERIS posted adjusted EPS of $2.32, matching the Zacks Consensus Estimate, with an average surprise of 0.61% over the last four quarters [1][3]. Segment Analysis - **Healthcare**: Growth in consumables and services is expected to continue, driven by increased procedure volumes in the U.S. and market share gains [4]. The revenue for Healthcare capital equipment is projected to improve by 4.1% year-over-year [6]. - **Applied Sterilization Technologies (AST)**: Organic revenue growth is anticipated, with a projected increase of 9% year-over-year for this segment [7][8]. Despite previous declines in capital equipment shipments, demand in bioprocessing is expected to contribute positively [7]. - **Life Sciences**: This segment may see a revenue decline of 1.5% year-over-year, as strong growth in consumables and services is offset by a decrease in capital equipment revenue [9]. Estimate Revision Trend - Earnings estimates for STERIS have remained stable at $2.58 per share over the past 60 days, indicating confidence in the upcoming results [3]. Earnings ESP and Zacks Rank - STERIS has an Earnings ESP of 0.00%, suggesting a lower likelihood of beating earnings expectations [11]. The company currently holds a Zacks Rank of 3 (Hold) [11].